Month: August 2024

INVESTOR NEWS no. 57 – 8 August 2024 DFDS expects to publish the report for Q2 2024 on 14 August 2024 at around 07:30 CET. Torben Carlsen, CEO, and Karen Boesen, CFO, will present the report on a live conference call. The presentation will be followed by a Q&A session. Investors, analysts and other interested parties are invited to take part.Conference call Date:        14 August 2024Time:        10:00 CETRegistration:        Register ahead of the call via this link. Access code is mailedafter registration. Live-streaming of the conference call is available from this link.Contact Søren Brøndholt Nielsen, IR +45 33 42 33 59About DFDS We operate a transport network in and around Europe with an annual revenue of DKK 28bn and 14,000 full-time employees. We move goods in trailers by ferry, road & rail, and we offer...

INVESTOR NEWS no. 57 – 8 August 2024 DFDS expects to publish the report for Q2 2024 on 14 August 2024 at around 07:30 CET. Torben Carlsen, CEO, and Karen Boesen, CFO, will present the report on a live conference call. The presentation will be followed by a Q&A session. Investors, analysts and other interested parties are invited to take part. Conference call Date:        14 August 2024Time:        10:00 CETRegistration:        Register ahead of the call via this link. Access code is mailedafter registration. Live-streaming of the conference call is available from this link.Contact Søren Brøndholt Nielsen, IR +45 33 42 33 59About DFDS We operate a transport network in and around Europe with an annual revenue of DKK 28bn and 14,000 full-time employees. We move goods in trailers by ferry, road & rail, and we offer...

Patents issued in mainland China protect the Company’s novel secreted Klotho protein and Its gene delivery system Recent Patents issued in Hong Kong and Shanghai support protection to develop treatments for Alzheimer’s Disease and other neurodegenerative diseasesNEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) — ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a US-based biotechnology company focused on developing cell- and gene-based treatments to affect aging and age-related diseases, announces the grant and issuance of patent number HK1259628 protecting the development of novel genetic approaches for the treatment of neurodegenerative diseases to include Alzheimer’s disease, Parkinson’s diseases and amyotrophic lateral sclerosis (“ALS”). The Company previously announced that it had been granted this key patent in China...

CALGARY, Alberta, Aug. 08, 2024 (GLOBE NEWSWIRE) — Petrus Resources Ltd. (“Petrus” or the “Company”) (TSX: PRQ) is pleased to announce that a conference call to discuss the Company’s second quarter 2024 earnings will be held on August 8, 2024 at 9:00 AM MT (11:00 AM EST). For further details and to access the conference call information, please visit: www.petrusresources.com/events ABOUT PETRUSPetrus is a public Canadian oil and gas company focused on property exploitation, strategic acquisitions and risk-managed exploration in Alberta. FOR FURTHER INFORMATION PLEASE CONTACT:Ken Gray President and Chief Executive Officer T: 403-930-0889 E: kgray@petrusresources.com

SHENZHEN, China, Aug. 08, 2024 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today released a summary of an interview of its Chief Financial Officer, Mr. Shan-Nen Bong with an overseas financial magazine. Interview summary: Interviewer: In the past four quarterly earnings reports, I noticed that your company’s gross margin remained between 65% and 72%. This is a fairly high level. Could you explain the main reasons for this high gross margin? Mr. Shan-Nen Bong: There are several driving factors behind this. First, we have adjusted our revenue structure in terms of businesses, strategically reducing low-margin businesses and investing more resources in high-margin products & services, thereby...

ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2024 8 AUGUST 2024 at 12:00 EEST Orion Group Half-Year Financial Report January–June 2024Net sales totalled EUR 636.7 (January–June 2023: 567.5) million Operating profit was EUR 121.8 (102.0) million Basic earnings per share were EUR 0.68 (0.57) Cash flow from operating activities per share was EUR 0.98 (0.27) The outlook for 2024 was upgraded after the reporting period on 1 July 2024: Net sales are estimated to be EUR 1,440 million to EUR 1,480 million. Operating profit is estimated to be EUR 350 million to EUR 380 million. Previously net sales were estimated to be EUR 1,340 to EUR 1,410 and operating profit was estimated to be EUR 280 million to EUR 310 million.Key figures  4-6/24 4-6/23 Change % 1–6/24 1–6/23 Change % 1-12/23Net sales, EUR million 328.2...

PRESS RELEASE                                         Share Buyback Transaction Details August 1 – August 7, 2024 Alphen aan den Rijn – August 8, 2024 – Wolters Kluwer (Euronext: WKL), a global leader in professional information, software solutions, and services, today reports that it has repurchased 122,009 its own ordinary shares in the period from August 1, 2024, up to and including August 7, 2024, for €18.2 million and at an average share price of €149.40. These repurchases are part of the share buyback program announced on February 21, 2024, under which we intend to repurchase shares for €1 billion during 2024. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2024Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€)...

Partnership leverages Medigene’s leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics’ unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispecific antibody platform WuXiBody™ Collaboration is a three-year and potentially multi-TCR program partnershipPlanegg/Martinsried, August 8, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and WuXi Biologics (stock code: 2269.HK) enter into a three-year, multi-target strategic partnership to design and co-research T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors. The collaboration combines the respective expertise of each company with Medigene’s 3S (sensitive, specific and safe) TCR generation and characterization capabilities and WuXi Biologics’ unique anti-CD3 mAb, its...